Lead Product(s) : COVID-19 Vaccine Recombinant, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Laboratorios HIPRA
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims for the commercialisation of HIPRA's mRNA COVID-19 vaccine, Bimervax, which combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, in the United Kingdom.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 08, 2023
Lead Product(s) : COVID-19 Vaccine Recombinant, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Laboratorios HIPRA
Deal Size : Undisclosed
Deal Type : Agreement